Vistagen Therapeutics Inc (VTGN)

01:15 AM

Head to Head Survey: Aquestive Therapeutics (NASDAQ:AQST) & Vistagen Therapeutics (NASDAQ:VTGN) - Defense World

01:15 AM

Jan 16, 2025

Jane Street Group LLC Purchases Shares of 19,659 Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Jan 16, 2025

Jan 15, 2025

Vistagen reports positive outcomes from Phase IIA cancer cachexia trial - Yahoo Finance

Jan 15, 2025

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study By Investing.com - Investing.com Canada

Jan 14, 2025

Jan 14, 2025

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia - sharewise

Jan 14, 2025

Jan 14, 2025

Vistagen reports promising PH284 nasal spray study - Investing.com

Jan 14, 2025

Jan 11, 2025

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Geode Capital Management LLC - Defense World

Jan 11, 2025

Jan 10, 2025

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder - sharewise

Jan 10, 2025

Dec 27, 2024

HighTower Advisors LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Dec 27, 2024

Dec 19, 2024

VTGN stock touches 52-week low at $2.38 amid market challenges - Investing.com India

Dec 19, 2024

Dec 18, 2024

VTGN stock touches 52-week low at $2.38 amid market challenges By Investing.com - Investing.com South Africa

Dec 18, 2024

Dec 12, 2024

Mental Disorder Treatment Market Innovations and Key Players: - openPR

Dec 12, 2024

Dec 12, 2024

PD-LID Market Growth to Accelerate in Forecast Period - openPR

Dec 12, 2024

Dec 11, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges By Investing.com - Investing.com South Africa

Dec 11, 2024

Dec 10, 2024

VTGN Stock Touches 52-Week Low at $2.47 Amid Market Challenges - Investing.com

Dec 10, 2024

Nov 30, 2024

VTGN (Vistagen Therapeutics) Inventory Turnover : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 27, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Great Point Partners LLC - MarketBeat

Nov 27, 2024

Nov 26, 2024

Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World

Nov 26, 2024

Nov 22, 2024

VTGN Stock Touches 52-Week Low at $2.51 Amid Market Challenges - Investing.com India

Nov 22, 2024

Nov 21, 2024

Anxiety drug trials keep Stifel optimistic on VistaGen stock's upside potential - Investing.com Canada

Nov 21, 2024

Nov 21, 2024

Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World

Nov 21, 2024

Nov 17, 2024

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Down 18.1% in October - Defense World

Nov 17, 2024

Nov 15, 2024

Great Point Partners LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Citadel Advisors LLC Increases Stake in Vistagen Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Vistagen Therapeutics adds SKDK, GCI Health alum Michelle Peters Wellington - MM+M Online

Nov 14, 2024

Nov 14, 2024

Vistagen CEO to Present at Stifel 2024 Healthcare Conference | VTGN Stock News - StockTitan

Nov 14, 2024

Nov 11, 2024

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

Nov 11, 2024

Q1 Earnings Estimate for VTGN Issued By William Blair - MarketBeat

Nov 11, 2024

Nov 08, 2024

VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates - MSN

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlight - GuruFocus.com

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... - Yahoo Finance

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... By GuruFocus - Investing.com Canada

Nov 08, 2024

Nov 08, 2024

Vistagen Therapeutics Reports Increased R&D Expenses - TipRanks

Nov 08, 2024

Nov 07, 2024

Vistagen Therapeutics Inc Reports Q2 2025 Revenue of $183,000, M - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update - Business Wire

Nov 07, 2024

Nov 07, 2024

Vistagen reports Q2 EPS (42c), consensus (39c) - TipRanks

Nov 07, 2024

Nov 06, 2024

Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect - GuruFocus.com

Nov 06, 2024

Nov 05, 2024

Vistagen to Present at the 2024 Neuroscience Education Institute Congress - Business Wire

Nov 05, 2024

Nov 02, 2024

Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday - MarketBeat

Nov 02, 2024

Nov 01, 2024

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 - sharewise

Nov 01, 2024

Oct 31, 2024

VTGN (Vistagen Therapeutics) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com

Oct 31, 2024

Oct 21, 2024

Generalized Anxiety Disorder Pipeline 2024: Clinical Trials - openPR

Oct 21, 2024

Oct 15, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder - Seeking Alpha

Oct 15, 2024

Oct 12, 2024

VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know - MSN

Oct 12, 2024